Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Go back to Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 124.40 -2.35 (1.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.75 | 52 Week High | $118.49 | |||
| Open | $124.11 | 52 Week Low | $55.00 | |||
| Day High | $126.40 | P/E | N/A | |||
| Day Low | $122.22 | EPS | $-0.56 | |||
| Volume | 1,276,377 | |||||
| (NASDAQ: MIRM) | Delayed: 99.53 -1.37 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $100.90 | 52 Week High | $ | |||
| Open | $98.49 | 52 Week Low | $ | |||
| Day High | $101.83 | P/E | N/A | |||
| Day Low | $97.65 | EPS | $ | |||
| Volume | 638,058 | |||||
